TBX™ products for treating metabolic inflammatory & cancer diseases
Engineering phages for precision delivery of DNA Cargo to target bacteria
Innovating DNA Cargos by combining CRISPR & synthetic biology science
Oral delivery of TBX™ products for in vivo production of biotherapeutics
Deliver bacteria (FMT or LBP) to modify microbiome composition, or use phages to kill bacteria to treat infectious diseases
Lack of effective colonization; The transient nature of the microbiome; Dysbiosis
Harnessing our own microbiome bacteria as an in vivo port for secreting biotherapeutics; Robust and durable efficacy; No disruption to the microbiome.
Our dedicated founders, scientific team and investors are committed to develop life saving therapeutics